EPISODE · Feb 3, 2026 · 1H
The Glucose Sensor That Predicts the Future with Mark Tapsak
from The Crux of Medtech · host Crux of Medtech
In this episode, Henry Norton sits down with Mark Tapsak, Chief Science Officer at Glucotrack and one of Dexcom's earliest employees.Mark Tapsak left Medtronic for a "crazy startup" called Dexcom after seeing data so compelling he couldn't say no. Two decades later, he's back in the CGM game as Chief Science Officer at Glucotrack, working on a 3-year implantable sensor that lives in the bloodstream.Key Topics:Mark's path from blue-collar Minnesota to polymer chemistry PhDThe founding days of Dexcom and the "three fathers" of CGM (Goff, Updike, Heller)Why early CGM struggled to convince endocrinologists of continuous data's valueDexcom's pivot from implantable to short-term sensorsGlucotrack's evolution from non-invasive ear clip to intravascular 3-year sensorCurrent trial progress in Brazil and Australia, and the path to US IDERelated Insights:Why implanting devices in the body is "harder than going to the moon"The business case for long-term implantables vs. wearablesHow the immune response creates a "sleep period" that tanks glucose signalsWhy timing and market readiness matter as much as technologyCore Challenges:Early CGM implantables worked in only ~50% of patients, forcing a pivot to wearables and delaying long-term solutions by decades.Glucotrack is now targeting a 3-year intravascular sensor that bypasses the aggressive subcutaneous immune response, with US trials expected in 2026.🎧 Tune in now to hear how CGM went from academic curiosity to medical device success story, and what comes next.The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx, click here.A big thank you to our sponsors on this season of the podcast; TTP plc With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, TTP plc can accelerate your development with the latest technologies. Learn more at TTP.com
What this episode covers
In this episode, Henry Norton sits down with Mark Tapsak, Chief Science Officer at Glucotrack and one of Dexcom's earliest employees.Mark Tapsak left Medtronic for a "crazy startup" called Dexcom after seeing data so compelling he couldn't say no. Two decades later, he's back in the CGM game as Chief Science Officer at Glucotrack, working on a 3-year implantable sensor that lives in the bloodstream.Key Topics:Mark's path from blue-collar Minnesota to polymer chemistry PhDThe founding days of Dexcom and the "three fathers" of CGM (Goff, Updike, Heller)Why early CGM struggled to convince endocrinologists of continuous data's valueDexcom's pivot from implantable to short-term sensorsGlucotrack's evolution from non-invasive ear clip to intravascular 3-year sensorCurrent trial progress in Brazil and Australia, and the path to US IDERelated Insights:Why implanting devices in the body is "harder than going to the moon"The business case for long-term implantables vs. wearablesHow the immune response creates a "sleep period" that tanks glucose signalsWhy timing and market readiness matter as much as technologyCore Challenges:Early CGM implantables worked in only ~50% of patients, forcing a pivot to wearables and delaying long-term solutions by decades.Glucotrack is now targeting a 3-year intravascular sensor that bypasses the aggressive subcutaneous immune response, with US trials expected in 2026.🎧 Tune in now to hear how CGM went from academic curiosity to medical device success story, and what comes next.The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx, click here.A big thank you to our sponsors on this season of the podcast; TTP plc With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, TTP plc can accelerate your development with the latest technologies. Learn more at TTP.com
NOW PLAYING
The Glucose Sensor That Predicts the Future with Mark Tapsak
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m